Methylation of promoters of microRNAs and their host genes in myelodysplastic syndromes

References

• Swerdlow SH, Campo E, Harris NL, et al editors. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC Press; 2008.
   Google Scholar
• Cogle CR, Craig BM, Rollison DE, et al. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood 2011;117: 7121–7125.
   PubMed Web of Science ®Google Scholar
• Starczynowski DT, Vercauteren S, Sung S, et al. Copy number alterations at polymorphic loci may be acquired somatically in patients with myelodysplastic syndromes. Leuk Res 2011;35:444–447.
   PubMed Web of Science ®Google Scholar
• Starczynowski DT, Vercauteren S, Telenius A, et al. High-resolution whole genome tiling path array CGH analysis of CD34 + cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival. Blood 2008;112:3412–3424.
   PubMed Web of Science ®Google Scholar
• Vercauteren SM, Sung S, Starczynowski DT, et al. Array comparative genomic hybridization of peripheral blood granulocytes of patients with myelodysplastic syndrome detects karyotypic abnormalities. Am J Clin Pathol 2010;134:119–126.
   PubMed Web of Science ®Google Scholar
• Figueroa ME, Skrabanek L, Li Y, et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 2009;114:3448–3458.
   PubMed Web of Science ®Google Scholar
• Malcovati L, Papaemmanuil E, Bowen DT, et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood 2011;118: 6239–6246.
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Cazzola M, Boultwood J, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011;365:1384–1395.
   PubMed Web of Science ®Google Scholar
• Patnaik MM, Lasho TL, Hodnefield JM, et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood 2012;119:569–572.
   PubMed Web of Science ®Google Scholar
• Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011;478:64–69.
   PubMed Web of Science ®Google Scholar
• Obernosterer G, Tafer H, Martinez J. Target site effects in the RNA interference and microRNA pathways. Biochem Soc Trans 2008;36:1216–1219.
   PubMed Web of Science ®Google Scholar
• Garzon R, Croce CM. MicroRNAs in normal and malignant hematopoiesis. Curr Opin Hematol 2008;15:352–358.
   PubMed Web of Science ®Google Scholar
• Pelosi E, Labbaye C, Testa U. MicroRNAs in normal and malignant myelopoiesis. Leuk Res 2009;33:1584–1593.
   PubMed Web of Science ®Google Scholar
• Erdogan B, Facey C, Qualtieri J, et al. Diagnostic microRNAs in myelodysplastic syndrome. Exp Hematol 2011;39:915–926.e2.
   PubMed Web of Science ®Google Scholar
• Tiu RV, Gondek LP, O’Keefe CL, et al. Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Blood 2011;117:4552–4560.
   PubMed Web of Science ®Google Scholar
• Rodriguez A, Griffiths-Jones S, Ashurst JL, et al. Identification of mammalian microRNA host genes and transcription units. Genome Res 2004;14:1902–1910.
   PubMed Web of Science ®Google Scholar
• Baskerville S, Bartel DP. Microarray profiling of microRNAs reveals frequent coexpression with neighboring miRNAs and host genes. RNA 2005;11:241–247.
   PubMed Web of Science ®Google Scholar
• Ronchetti D, Lionetti M, Mosca L, et al. An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma. BMC Med Genomics 2008;1:37.
   PubMed Web of Science ®Google Scholar
• Breitman TR, Selonick SE, Collins SJ. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci USA 1980;77:2936–2940.
   PubMed Web of Science ®Google Scholar
• Fatica A, Rosa A, Ballarino M, et al. Role of microRNAs in myeloid differentiation. Biochem Soc Trans 2008;36:1201–1205.
   Google Scholar
• Mills KI, Kohlmann A, Williams PM, et al. Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome. Blood 2009;114:1063–1072.
   PubMed Web of Science ®Google Scholar
• Kaminskas E, Farrell A, Abraham S, et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 2005;11:3604–3608.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006;106:1794–1803.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, O’Brien S, Huang X, et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer 2007;109:1133–1137.
   PubMed Web of Science ®Google Scholar
• Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006;24:3895–3903.
   PubMed Web of Science ®Google Scholar
• Damm F, Thol F, Kosmider O, et al. SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications. Leukemia 2012;26:1137–1140.
   PubMed Web of Science ®Google Scholar
• Boultwood J. The role of haploinsufficiency of RPS14 and p53 activation in the molecular pathogenesis of the 5q- syndrome. Pediatr Rep 2011;3(Suppl. 2):e10.
   Google Scholar
• Czibere A, Bruns I, Junge B, et al. Low RPS14 expression is common in myelodysplastic syndromes without 5q- aberration and defines a subgroup of patients with prolonged survival. Haematologica 2009;94:1453–1455.
   PubMed Web of Science ®Google Scholar
• Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 2008;451:335–339.
   PubMed Web of Science ®Google Scholar
• Pellagatti A, Hellstrom-Lindberg E, Giagounidis A, et al. Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes. Br J Haematol 2008;142:57–64.
   PubMed Web of Science ®Google Scholar
• Zhang CC, Lodish HF. Insulin-like growth factor 2 expressed in a novel fetal liver cell population is a growth factor for hematopoietic stem cells. Blood 2004;103:2513–2521.
   PubMed Web of Science ®Google Scholar
• Murrell A, Ito Y, Verde G, et al. Distinct methylation changes at the IGF2-H19 locus in congenital growth disorders and cancer. PloS One 2008;3:e1849.
   PubMed Web of Science ®Google Scholar
• Bock O, Schlue J, Kreipe H. Reduced expression of H19 in bone marrow cells from chronic myeloproliferative disorders. Leukemia 2003;17:815–816.
   PubMed Web of Science ®Google Scholar
• Hofmann WK, Takeuchi S, Frantzen MA, et al. Loss of genomic imprinting of insulin-like growth factor 2 is strongly associated with cellular proliferation in normal hematopoietic cells. Exp Hematol 2002;30:318–323.
   PubMed Web of Science ®Google Scholar
• Morison IM, Eccles MR, Reeve AE. Imprinting of insulin-like growth factor 2 is modulated during hematopoiesis. Blood 2000;96:3023–3028.
   PubMed Web of Science ®Google Scholar
• Tessema M, Langer F, Bock O, et al. Down-regulation of the IGF-2/H19 locus during normal and malignant hematopoiesis is independent of the imprinting pattern. Int J Oncol 2005;26:499–507.
   PubMed Web of Science ®Google Scholar
• Maddika S, Kavela S, Rani N, et al. WWP2 is an E3 ubiquitin ligase for PTEN. Nat Cell Biol 2011;13:728–733.
   PubMed Web of Science ®Google Scholar
• Takaku M, Ueno H, Kurumizaka H. Biochemical analysis of the human ENA/VASP-family proteins, MENA, VASP and EVL, in homologous recombination. J Biochem 2011;149:721–729.
   PubMed Web of Science ®Google Scholar
• Zorzano A, Hernandez-Alvarez MI, Palacin M, et al. Alterations in the mitochondrial regulatory pathways constituted by the nuclear co-factors PGC-1alpha or PGC-1beta and mitofusin 2 in skeletal muscle in type 2 diabetes. Biochim Biophys Acta 2010;1797:1028–1033.
   PubMed Web of Science ®Google Scholar
• Chen C. microRNAs in myelodysplastic syndromes: how much do we know and not know?. Leuk Res 2013;37:241–242.
   PubMed Web of Science ®Google Scholar